Annette E. Fleckenstein, MS, PhD

Research Interests

  • Neuropharmacology
  • Neurochemistry
  • Aminergic Transporters
  • Addiction

Languages

  • English

Academic Information

  • Departments: Dentistry - Professor

Academic Office Information

  • 801-585-7474
  • Ray and Tye Noorda Oral Health Sciences Building
    530 South Wakara Way, Room: 3178
    Salt Lake City, UT 84108

Education History

Type School Degree
Postdoctoral Fellowship Department of Pharmacology and Toxicology, University of Utah
Postdoctoral Trainee
Postdoctoral Fellow
Postdoctoral Fellowship National Institutes of Health, National Institute on Drug Abuse (NIDA) - Addiction Research Center
Intramural Research Training Award
Postdoctoral Fellow
Doctoral Training Michigan State University
Pharmacology and Toxicology
Ph.D.
Graduate Training Western Michigan University
Biological Sciences
M.S.
Undergraduate Western Michigan University
Biomedical Sciences
B.S.

Selected Publications

Journal Article

  1. Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR (2015). Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug Alcohol Depend, 146, 30-8.
  2. McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE (2015). Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure. Neuropharmacology, 93, 146-54.
  3. Vieira-Brock PL, McFadden LM, Nielsen SM, Smith MD, Hanson GR, Fleckenstein AE (2015). Nicotine Administration Attenuates Methamphetamine-Induced Novel Object Recognition Deficits.LID - pyv073 [pii]LID - 10.1093/ijnp/pyv073 [doi]. Int J Neuropsychopharmacol, 18(12).
  4. Vieira-Brock PL, McFadden LM, Nielsen SM, Ellis JD, Walters ET, Stout KA, McIntosh JM, Wilkins DG, Hanson GR, Fleckenstein AE (2015). Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits. J Pharmacol Exp Ther, 355(3), 463-72.
  5. McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE (2014). Methamphetamine self-administration attenuates hippocampal serotonergic deficits: role of brain-derived neurotrophic factor. Int J Neuropsychopharmacol, 17(8), 1315-20.
  6. German CL, Hoonakker AH, Fleckenstein AE, Hanson GR (2014). Mephedrone alters basal ganglia and limbic neurotensin systems. J Neurochem, 130(3), 402-7.
  7. Baladi MG, Newman AH, Nielsen SM, Hanson GR, Fleckenstein AE (2014). Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia. Eur J Pharmacol, 732, 105-10.
  8. German CL, Alburges ME, Hoonakker AJ, Fleckenstein AE, Hanson GR (2014). Mephedrone alters basal ganglia and limbic dynorphin systems.LID - 10.1002/syn.21778 [doi]. (Epub ahead of print) Synapse.
  9. Baladi MG, Nielsen SM, Umpierre A, Hanson GR, Fleckenstein AE (2014). Prior methylphenidate self-administration alters the subsequent reinforcing effects of methamphetamine in rats. Behav Pharmacol, 25(8), 758-65.

Review

  1. German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE (2015). Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. [Review]. Pharmacol Rev, 67(4), 1005-24.
  2. German CL, Fleckenstein AE, Hanson GR (2014). Bath salts and synthetic cathinones: an emerging designer drug phenomenon. [Review]. Life Sci, 97(1), 2-8.

Book

  1. Hanson GR, Venturelli PJ, Fleckenstein AE (2006). Drugs and Society (9th Edition). Boston, MA: Jones and Bartlett.
  2. Hanson GR, Venturelli PJ, Fleckenstein AE (2004). Drugs and Society (8th Edition). Boston, MA: Jones and Bartlett.
  3. Hanson GR, Venturelli PJ, Fleckenstein AE (2002). Drugs and Society (7th Edition). Boston, MA: Jones and Bartlett.
  4. Hanson GR, Venturelli PJ, Fleckenstein AE, contributing author (2000). Drugs and Society (6th Edition). Boston, MA: Jones and Bartlett.